These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 8673716)

  • 1. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
    Petersein J; Saini S; Weissleder R
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

  • 3. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
    Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
    AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Overview of MRI contrast media. The case of endorem].
    Duroux M
    Radiologe; 1995 Nov; 35(11 Suppl 2):S247-8. PubMed ID: 8588029
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatic MRI with SPIO: detection and characterization of focal liver lesions.
    Reimer P; Tombach B
    Eur Radiol; 1998; 8(7):1198-204. PubMed ID: 9724439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Superparamagnetic iron oxide particles: what value has the T1 effect in the MR diagnosis of focal liver lesions?].
    Urhahn R; Adam G; Busch N; Chen JH; Euringer W; Günther RW
    Rofo; 1996 Oct; 165(4):364-70. PubMed ID: 8963049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The MR tomography of focal liver lesions with the superparamagnetic contrast agent AMI-25 at 1.5 tesla].
    Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
    Rofo; 1994 Jan; 160(1):46-51. PubMed ID: 8305692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
    Mergo PJ; Helmberger T; Nicolas AI; Ros PR
    AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver MR imaging with iron oxides: toward consensus and clinical practice.
    Weissleder R
    Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
    [No Abstract]   [Full Text] [Related]  

  • 11. Radiation induced liver injury detected by particulate reticuloendothelial contrast agent.
    Padhani AR; Husband JE; Gueret Wardle D
    Br J Radiol; 1998 Oct; 71(850):1089-92. PubMed ID: 10211072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging.
    Shamsi K; Balzer T; Saini S; Ros PR; Nelson RC; Carter EC; Tollerfield S; Niendorf HP
    Radiology; 1998 Feb; 206(2):365-71. PubMed ID: 9457187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of MR contrast agents for evaluating liver disease.
    Ward J; Robinson PJ
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Focal intrahepatic siderosis, diagnostic pitfall, iatrogenic image].
    Arteaga C; Raillat A; Salamand P; Debonne JM; Bonnet D; Martet G; Veuillet MO; Battini-Nouzille A; Briant JF
    J Radiol; 1998 Feb; 79(2):157-8. PubMed ID: 9757234
    [No Abstract]   [Full Text] [Related]  

  • 16. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases].
    Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ
    Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
    Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
    J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
    [No Abstract]   [Full Text] [Related]  

  • 18. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
    Saini S; Edelman RR; Li W; Petersein J; Hahn PF
    Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.